Dr. Lois Mulligan appointed Bracken Chair, Genetics and Molecular Medicine
Dean Jane Philpott is pleased to announce that Teri Shearer, Interim Provost and Vice-Principal (Academic) has appointed Dr. Lois Mulligan as the Bracken Chair in Genetics and Molecular Medicine effective July 1, 2023 for a five-year term. Her appointment was recommended by the Advisory Search Committee, chaired by Dr. David Berman, Head of the Department of Pathology and Molecular Medicine.
Dr. Mulligan completed her PhD in Biology at Queen’s University and underwent further training in the molecular genetics of rare cancer syndromes. She is a Principal Investigator in the Division of Cancer Biology and Genetics, Queen’s Cancer Research Institute, and a Professor in the Departments of Biomedical and Molecular Sciences, Pediatrics, and Pathology and Molecular Medicine (where she also serves as Associate Head, Education).
Dr. Mulligan’s research program seeks to understand the molecular, cellular, and clinical roles of the RET receptor tyrosine kinase in normal and cancer cells. Her research into the underlying molecular mechanisms causing inherited thyroid cancers led to the discovery of the role of the RET oncogene in endocrine tumours and has highlighted its contributions to a number of other difficult to manage cancers, ultimately promoting development of improved RET targeting therapies.
A highly regarded researcher and colleague, Dr. Mulligan has won numerous awards for teaching and research throughout her career including the Premier’s Research Excellence Award, Queen’s Chancellor’s Research Award and the Mihran and Mary Basmajian Award. She is currently an Advisory Editor of Endocrine Related Cancer, Chair of the Scientific and Research Committee of the North American Neuroendocrine Tumor Society and Director of the Collaborative Graduate Program in Cancer Research here at Queen’s.
Please join Dean Philpott in congratulating Dr. Mulligan on her appointment.